Sygnature collaborates with SilcsBio for software
Sygnature Discovery collaborates with software firm SilcsBio to offer SILCS and SSFEP software
Nottingham, UK—Today Sygnature Discovery, a drug discovery and preclinical services company, announced a collaboration with SilcsBio, a software company focused on high-throughput fully atomistic simulations of protein targets and protein-ligand structures. SilcsBio has provided Sygnature with access to its SILCS (Site Identification by Ligand Competitive Saturation) and SSFEP (Single Step Free Energy Perturbation) software. Sygnature will now able to offer clients the benefits of these techniques in their drug discovery projects.
The SILCS software identifies binding site hot spots on a protein’s surface. This could, potentially, include “cryptic pockets” – binding sites for which little structural information is available. SILCS methodology involves performing molecular dynamics simulations on a protein in an aqueous solution of chemically diverse small molecules. This generates probability distributions of fragment types, termed FragMaps.
These FragMaps can be used rapidly and with minimal computational expense to predict or refine ligand binding poses, quantitatively score ligands in the binding pocket and generate multiple receptor-based pharmacophore models for use in virtual screening campaigns. This has been shown to be a more effective technique than standard docking studies or receptor-based pharmacophore modeling.
“SilcsBio software suite, with its robust physics-based algorithms and user-friendly interface, provides great leverage in the structure-based drug design area and enables us to rapidly validate new ideas/hypothesis,” said Bill Tatsis, computational chemist at Sygnature Discovery.
In a complementary manner, the SSFEP software has demonstrated success in ranking compound binding affinities to target proteins. In particular, the SSFEP approach is about 1000-fold faster than the more widely used FEP methodology. It achieves this speed by post-processing molecular dynamics simulation data of a ligand, and using it to estimate the alchemical free energy change of chemically modifying that ligand.
Such a rapid assessment of the drug design team’s ideas could be advantageous in speeding up the design-test-optimize cycle. Being able to evaluate and prioritize design ideas in just a few days can have a significant impact in structure-based design projects.
In the past six months, Sygnature has applied the SilcsBio software suite successfully in various hit-to-lead and lead optimization projects. The company believes these new software tools will offer substantial benefits to its customers, not least because of the time savings the software can provide.
“We’re delighted to be collaborating with Sygnature Discovery to bring the advantages of our drug design software to Sygnature’s projects and customers,” mentioned Ken Malone, chief executive officer of SilcsBio. “This collaboration is very meaningful to us as Sygnature continues to be a great partner and it opens the door to new markets for SilcsBio.”